Large artery inflammation in systemic lupus erythematosus

Area of Science:

• Cardiovascular Medicine
• Rheumatology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease associated with increased cardiovascular risk.
• Traditional cardiovascular risk factor management may be insufficient in SLE patients.
• Accelerated atherosclerosis is a significant concern in individuals with SLE.

Observation:

• A young African-American woman with recurrent pneumonias presented with symptoms suggestive of cardiovascular compromise.
• Histologic examination revealed lupus aortitis, indicating vascular inflammation.
• Subclinical inflammation in medium-sized vessels may be a modifiable risk factor in SLE.

Findings:

• Optimal Framingham risk factor management alone may not fully mitigate the excess atherosclerosis risk in SLE.
• Low-grade SLE disease activity in medium-sized vessels could be a critical modifiable cardiovascular risk factor.
• Widespread subclinical vessel inflammation in lupus contributes significantly to accelerated atherosclerosis.

Implications:

• Lowering the threshold for aggressive, disease-modifying treatment in lupus is warranted.
• A "treat-to-target" approach focusing on lupus disease activity may improve cardiovascular outcomes.
• Further research into vascular inflammation in SLE is essential for refining patient management strategies.